Document is current
Any future updates will be listed below
-
Authors
Rivera-Pérez, Cristina
Morgades, Mireia
Alonso-Saladrigues, Anna
Montesinos, Pau
Murciano, Thais
Gil, Cristina
Adán, Rosa
Esteve, Jordi
Fuentes, Carolina
Amigo, María Luz
González-Martínez, Berta
Coll, Rosa
Dapena, José Luis
de Llano, María Paz Queipo
Fuster, José Luis
García-Cadenas, Irene
Tasso, María
Barba, Pere
Rives, Susana https://orcid.org/0000-0002-5658-1831
Ribera, Josep Maria
-
Funding
Funding for this research was provided by:
Fundació Institució dels Centres de Recerca de Catalunya
- License Information
-
More Information
Article History
Received: 3 October 2025
Accepted: 13 March 2026
First Online: 24 March 2026
Declarations
:
: C R-P has received honoraria and/or travel support from JazzPharma, Pfizer, Gebro, and OneChain Immunotherapeutics. A A-S has received honoraria and/or travel support from Novartis, JazzPharma, MSD, and OneChain Immunotherapeutics. P B has received Advisory Board and consultancy fees from Allogene, Amgen, Autolus, BMS/Celgene, Kite/Gilead, Incyte, Miltenyi Biomedicine, Novartis, Nektar, Pfizer, and Pierre Fabre. S R has received honoraria and/or travel support from Novartis, Servier, Celgene/ Bristol Myers Squibb, Kite/ Gilead, Pfizer, Clinigen, OneChain Immunotherapeutics, and Amgen, and reports being part of DMSB in clinical trial sponsored by Novartis and of a DMC in a clinical trial sponsored by Autolus. JM R reports consulting/advisory roles at Incyte, Pfizer, Bristol Myers Squibb, Novartis, and Takeda, and research funding from Amgen, Pfizer, and Incyte.
: The study was approved by the Institutional Review Board (IRB) of Hospital Sant Joan de Déu (PIC 98 − 22, available upon request) and Hospital Germans Trias i Pujol, which were the IRBs of reference for this study in Spain for pediatric and adult patients, respectively. Patients (or, alternatively, their legal representatives) signed the informed consent form before inclusion in the study.
